Urology Search
Urology Urology
benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.

Benign Prostatic Hyperplasia Drug Information

Drug Information

Indication: Functional symptoms of benign prostatic hyperplasia (BPH).

Indication: HTN. Symptomatic relief of benign prostatic hyperplasia (BPH).

Indication: Bladder outlet obstruction associated w/ BPH in patients ≥50 yr.

Indication: Monotherapy or in combination w/ tamsulosin for treatment & control of symptomatic benign prostatic hyperp...

Indication: HTN & initial agent to control BP. In hypertensive or normotensive patients w/ benign prostatic hyperplasi...

Indication: Erectile dysfunction. 5 mg: Symptomatic treatment of benign prostatic hyperplasia (BPH).

Indication: Symptomatic benign prostatic hyperplasia (BPH). HTN.

Indication: Moderate to severe benign prostatic hyperplasia (BPH) symptoms; reduces risk of acute urinary retention & ...

Indication: HTN. Improve clinical symptoms & increase urine flow in benign prostatic hyperplasia.

Indication: HTN & benign prostatic hyperplasia (BPH).

1  /  2
1  /  2
Editor's Recommendations
Most Read Articles
What is the chief complaint of patients hospitalized with a first myocardial infarction?
5 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
High dose comparable to lower doses of ACE inhibitors for heart failure
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
How to control asthma well: Experts’ perspectives
Pearl Toh, 5 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pre-eclampsia bears increased hazard of heart failure
6 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.